Welcome to our dedicated page for Synaptogenix SEC filings (Ticker: SNPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Following how Synaptogenix finances years of bryostatin trials can feel like decoding lab notes and legalese at once. Risk factors stretch for pages, clinical milestones hide in footnotes, and dilution terms change with every equity raise—making Synaptogenix SEC filings explained simply a genuine need, not a luxury.
Stock Titan’s AI tackles this complexity the moment a document hits EDGAR. Our engine produces concise, plain-English highlights so you’re understanding Synaptogenix SEC documents with AI rather than wading through dense prose. Real-time alerts flag Synaptogenix Form 4 insider transactions real-time, while intuitive dashboards link segment spending, trial timelines, and cash runway directly to the passages that matter.
- 10-K & 10-Q – View the Synaptogenix annual report 10-K simplified and each Synaptogenix quarterly earnings report 10-Q filing with side-by-side AI notes that separate R&D cost trends from financing clauses.
- Form 4 – Instantly scan Synaptogenix insider trading Form 4 transactions and deeper Synaptogenix executive stock transactions Form 4 to spot buying or selling before trial read-outs.
- 8-K & Proxy – Get Synaptogenix 8-K material events explained and decode every Synaptogenix proxy statement executive compensation table into clear numbers.
Use these insights for tangible tasks: compare quarter-over-quarter cash burn with upcoming Phase II data, monitor management’s share activity ahead of material announcements, or export the Synaptogenix earnings report filing analysis straight into your model. With AI-powered summaries, real-time updates, and complete coverage, you’ll move from document hunting to decision making in minutes.
TAO Synergies (formerly Synaptogenix) has announced a special virtual stockholder meeting on August 6, 2025 to vote on three key proposals:
- Authorization to issue common stock underlying convertible preferred stock and warrants from a June 9, 2025 Securities Purchase Agreement, including 5,500 shares of Series D preferred stock convertible into 1,833,333 common shares at $3.00 per share, plus corresponding warrants
- Approval of amendments to the 2020 Equity Incentive Plan to increase available shares by 2 million and rename it to "TAO Synergies Inc. 2020 Equity Incentive Plan"
- Approval of a consulting agreement with James Altucher and Z-List Media, granting warrants for 1.2 million common shares at exercise prices ranging from $4.00 to $12.00 per share for crypto portfolio management and strategic services
The proposals require stockholder approval to comply with Nasdaq Listing Rules 5635(c) and 5635(d). The board recommends approval of all proposals. Record date for voting eligibility is June 9, 2025.
Synaptogenix (Nasdaq: SNPX) filed an 8-K reporting two material items: a leadership change and a corporate rebranding.
- CEO resignation: Dr. Alan J. Tuchman stepped down as Chief Executive Officer effective June 8 2025, but remains on the board and becomes Chief Medical Officer; his base salary is reduced to $7,500 per month.
- Name & ticker change: On June 26 2025 the company changed its name to TAO Synergies Inc. via a Delaware certificate of amendment. The Nasdaq symbol will switch from SNPX to TAOX on July 1 2025. No shareholder vote was required under DGCL §242.
The filing also corrects a prior 8-K that mistakenly said Dr. Tuchman resigned from the board; he continues as a director. Exhibits 3.1 and 99.1 provide the amendment and related press release.
Synaptogenix, Inc. (Nasdaq: SNPX) filed an 8-K on June 24, 2025 disclosing two related developments under Items 7.01 and 8.01.
First, the Company executed its initial purchase of the cryptocurrency “TAO” as the opening step in a previously announced digital-asset treasury strategy. Funding for the acquisition came directly from existing cash on the balance sheet; no external financing or equity issuance was mentioned.
Second, Synaptogenix appointed BitGo Trust Company, Inc. as its qualified custodian and trading partner. BitGo will (1) hold the Company’s TAO in regulated, insured cold storage, (2) facilitate additional TAO purchases via its platforms and OTC desk, and (3) enable TAO to be staked directly from custody. Management states that staking has already begun to generate revenue, positioning the digital-asset holdings as an income-producing treasury component while maintaining security and compliance.
No dollar amounts, number of tokens, staking yields, or risk-management parameters were provided in the filing. A press release containing the same information was furnished as Exhibit 99.1 and is expressly not incorporated by reference into Exchange Act filings.
Key investor takeaways:
- Synaptogenix is now exposed to cryptocurrency price volatility and operational risks.
- The partnership with a regulated custodian and the revenue-generating staking model signal an intent to treat TAO as a strategic, yield-bearing asset rather than a passive holding.
- Absence of quantitative disclosures limits assessment of materiality at this stage.
Synaptogenix has filed Form D for a completed offering of securities under Rule 506(b) of Regulation D. The biotechnology company raised $5.5 million through the sale of equity securities and warrants to 5 investors, with the offering closing on June 23, 2025.
Key details of the offering:
- Sales commissions totaled $385,000, paid to GP Nurmenkari Inc.
- Securities were offered in Illinois, New York, and Ohio
- The offering duration is less than one year
- No minimum investment requirement was specified
Company leadership includes Joshua Silverman as Executive Chairman, Robert Weinstein as CFO, and directors William Singer, Bruce T. Bernstein, and Jonathan L. Schechter. The company is headquartered in New York and was incorporated in Delaware over five years ago.
FAQ
What is the current stock price of Synaptogenix (SNPX)?
What is the market cap of Synaptogenix (SNPX)?
What is the primary focus of Synaptogenix?
How does Synaptogenix approach drug development?
What makes bryostatin a critical component of their pipeline?
Are there other therapeutic areas the company is exploring?
How does Synaptogenix strengthen its research capabilities?
What role does intellectual property play for Synaptogenix?
How is Synaptogenix positioned within the competitive biopharma landscape?
